ニクソア
Nyxoah S.A.
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.58 | $8M | -$20M |
| 2026 Q1 | -0.37 | $7M | -$22M |
| 2025 Q4 | -0.59 | $6M | -$13M |
| 2025 Q3 | -0.63 | $2M | -$21M |
| 2025 Q2 | -0.55 | $1M | -$17M |
| 2025 Q1 | -0.60 | $1M | -$19M |
| 2024 Q4 |
| -0.46 |
| $1M |
| -$14M |
| 2024 Q3 | -0.50 | $1M | -$14M |